Ally Bridge Group’s Solid Biosciences SLDB Stock Holding History

Ally Bridge Group’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.52M	Buy	766,974 +353,349	+85%	+$2.27M	4.46%	8
2025 Q4	$2.33M	Sell	413,625 -135,557	-25%	-$735K	2.43%	16
2025 Q3	$3.39M	Sell	549,182 -174,818	-24%	-$1.02M	2.06%	18
2025 Q2	$3.53M	Buy	+724,000	New	+$2.56M	2.93%	16

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ally Bridge Group's SLDB Position: Q1 2026 in Review

Ally Bridge Group increased its Solid Biosciences (SLDB) stake by 85% in Q1 2026, buying an estimated $2.27M and bringing the position to 766,974 shares worth $5.52M. The position accounts for 4.46% of the portfolio, ranked #8.

Ally Bridge Group first reported a position in SLDB in Q2 2025 and has held it in 4 quarters since. 150 funds tracked by Wall St. Rank hold SLDB as of Q1 2026.

Ally Bridge Group held 766,974 shares of Solid Biosciences worth $5.52M as of Q1 2026.
Ally Bridge Group bought 353,349 Solid Biosciences shares in Q1 2026, an estimated $2.27M.
Solid Biosciences made up 4.46% of Ally Bridge Group's portfolio in Q1 2026, its #8 holding.
Ally Bridge Group first reported a position in Solid Biosciences in Q2 2025 and has held it in 4 quarters since.
150 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.